| Frank Michael D'alessandro, Md Inc | |
|
2 Wake Robin Rd Ste 103 Lincoln RI 02865-4241 | |
| (401) 334-3105 | |
| (401) 334-1144 |
| Full Name | Frank Michael D'alessandro, Md Inc |
|---|---|
| Speciality | Internal Medicine |
| Location | 2 Wake Robin Rd, Lincoln, Rhode Island |
| Authorized Official Name and Position | Deborah A Lander (PRACTICE MANAGER) |
| Authorized Official Contact | 4013343105 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Frank Michael D'alessandro, Md Inc 2 Wake Robin Rd Ste 103 Lincoln RI 02865-4241 Ph: (401) 334-3105 | Frank Michael D'alessandro, Md Inc 2 Wake Robin Rd Ste 103 Lincoln RI 02865-4241 Ph: (401) 334-3105 |
| NPI Number | 1518944941 |
|---|---|
| Provider Enumeration Date | 12/28/2005 |
| Last Update Date | 07/10/2015 |
| Medicare PECOS PAC ID | 8123193869 |
|---|---|
| Medicare Enrollment ID | O20080815000009 |
News Archive
According to researchers at the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, the first-ever national estimate of the prevalence of autism in the United States has found that the disorder affects up to one in every 175 school-age children.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.
Researchers have found why some people are more susceptible to gout than others. The scientists looked at the genetic codes of more than 12,000 people after identifying a gene linked to uric acid levels in the blood.
Sepsis is a life-threatening condition that occurs when the body's immune response to infection spirals out of control.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518944941 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD8003 (Rhode Island) | Primary |
| Provider Name | Frank Michael D'alessandro |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1225018955 PECOS PAC ID: 1759275050 Enrollment ID: I20040720000671 |
News Archive
According to researchers at the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, the first-ever national estimate of the prevalence of autism in the United States has found that the disorder affects up to one in every 175 school-age children.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.
Researchers have found why some people are more susceptible to gout than others. The scientists looked at the genetic codes of more than 12,000 people after identifying a gene linked to uric acid levels in the blood.
Sepsis is a life-threatening condition that occurs when the body's immune response to infection spirals out of control.
› Verified 7 days ago
| Provider Name | Jean F Smith |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1043241615 PECOS PAC ID: 8224082870 Enrollment ID: I20050310000001 |
News Archive
According to researchers at the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, the first-ever national estimate of the prevalence of autism in the United States has found that the disorder affects up to one in every 175 school-age children.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.
Researchers have found why some people are more susceptible to gout than others. The scientists looked at the genetic codes of more than 12,000 people after identifying a gene linked to uric acid levels in the blood.
Sepsis is a life-threatening condition that occurs when the body's immune response to infection spirals out of control.
› Verified 7 days ago
| Provider Name | David J Ramos |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114227436 PECOS PAC ID: 1557545027 Enrollment ID: I20110407000105 |
News Archive
According to researchers at the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, the first-ever national estimate of the prevalence of autism in the United States has found that the disorder affects up to one in every 175 school-age children.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.
Researchers have found why some people are more susceptible to gout than others. The scientists looked at the genetic codes of more than 12,000 people after identifying a gene linked to uric acid levels in the blood.
Sepsis is a life-threatening condition that occurs when the body's immune response to infection spirals out of control.
› Verified 7 days ago
| Provider Name | Karen A Rugg |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730408220 PECOS PAC ID: 8426356692 Enrollment ID: I20160421001071 |
News Archive
According to researchers at the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, the first-ever national estimate of the prevalence of autism in the United States has found that the disorder affects up to one in every 175 school-age children.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.
Researchers have found why some people are more susceptible to gout than others. The scientists looked at the genetic codes of more than 12,000 people after identifying a gene linked to uric acid levels in the blood.
Sepsis is a life-threatening condition that occurs when the body's immune response to infection spirals out of control.
› Verified 7 days ago
| Provider Name | Faithe Weathers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750850665 PECOS PAC ID: 4486991528 Enrollment ID: I20190710001052 |
News Archive
According to researchers at the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, the first-ever national estimate of the prevalence of autism in the United States has found that the disorder affects up to one in every 175 school-age children.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.
Researchers have found why some people are more susceptible to gout than others. The scientists looked at the genetic codes of more than 12,000 people after identifying a gene linked to uric acid levels in the blood.
Sepsis is a life-threatening condition that occurs when the body's immune response to infection spirals out of control.
› Verified 7 days ago
News Archive
According to researchers at the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, the first-ever national estimate of the prevalence of autism in the United States has found that the disorder affects up to one in every 175 school-age children.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.
Researchers have found why some people are more susceptible to gout than others. The scientists looked at the genetic codes of more than 12,000 people after identifying a gene linked to uric acid levels in the blood.
Sepsis is a life-threatening condition that occurs when the body's immune response to infection spirals out of control.
› Verified 7 days ago
Endocrine Treatment Centers, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2 Wake Robin Rd, Suite 207, Lincoln, RI 02865 Phone: 401-334-2242 Fax: 401-334-0376 | |
Am Health Professionals Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1 Commerce St Ste 100, Lincoln, RI 02865 Phone: 401-793-8484 Fax: 401-793-8481 | |
Angela L. Karavasilis, Do, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2 Wake Robin Rd, Suite 208, Lincoln, RI 02865 Phone: 401-475-7650 Fax: 407-475-7655 | |
Michelle C. Vannieuwenhuize, Md Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 6 Blackstone Valley Pl, Building #3 Suite 305, Lincoln, RI 02865 Phone: 401-334-1097 Fax: 401-305-5497 | |
Breiter Tech Corp Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 640 George Washington Hwy, Lincoln, RI 02865 Phone: 216-386-3815 | |
Comprehensive Medical Care Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 132 Old River Rd, Suite 108, Lincoln, RI 02865 Phone: 401-334-1044 Fax: 401-334-1054 |